Clark, Kristina EN;
Giles, Ian;
(2024)
Updates on the antiphospholipid syndrome.
Medicine
, 52
(12)
pp. 778-785.
10.1016/j.mpmed.2024.09.003.
Preview |
Text
Giles_52-12ClarkGilesAS IG FINAL VERSION_edited - 140824 clean.pdf Download (437kB) | Preview |
Abstract
Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial, venous or microvascular thrombosis, and/or pregnancy morbidity or non-thrombotic manifestations in the presence of persistently positive antiphospholipid antibodies. APS can occur alone or in association with other autoimmune rheumatic disease and affects around 1 in 2000 people. Non-thrombotic inflammatory mechanisms are increasingly identified in the pathogenesis of APS, alongside a recognition that obstetric APS may be a specific subset of APS. Treatment remains focused on lifelong anticoagulation and the prevention of further thrombosis or obstetric complications. The identification of novel mechanisms is, however, leading the development of diagnostic tests and more targeted therapies to improve disease management.
| Type: | Article |
|---|---|
| Title: | Updates on the antiphospholipid syndrome |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.mpmed.2024.09.003 |
| Publisher version: | http://dx.doi.org/10.1016/j.mpmed.2024.09.003 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | β2-glycoprotein-1 antibodies; anticardiolipin antibodies; anticoagulation; antiphospholipid syndrome; complement; lupus anticoagulant; MRCP; obstetric morbidity; thrombosis |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10200491 |
Archive Staff Only
 |
View Item |
